Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Assets (2019 - 2025)

Historic Return on Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.75%.

  • BridgeBio Pharma's Return on Assets fell 1300.0% to 0.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75%, marking a year-over-year decrease of 1300.0%. This contributed to the annual value of 0.74% for FY2024, which is 3800.0% up from last year.
  • Per BridgeBio Pharma's latest filing, its Return on Assets stood at 0.75% for Q3 2025, which was down 1300.0% from 0.77% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Return on Assets ranged from a high of 0.51% in Q2 2021 and a low of 1.12% during Q4 2023
  • In the last 5 years, BridgeBio Pharma's Return on Assets had a median value of 0.75% in 2025 and averaged 0.77%.
  • Per our database at Business Quant, BridgeBio Pharma's Return on Assets tumbled by -3000bps in 2023 and then surged by 4900bps in 2024.
  • Over the past 5 years, BridgeBio Pharma's Return on Assets (Quarter) stood at 0.69% in 2021, then decreased by -25bps to 0.87% in 2022, then fell by -29bps to 1.12% in 2023, then skyrocketed by 40bps to 0.66% in 2024, then fell by -13bps to 0.75% in 2025.
  • Its Return on Assets stands at 0.75% for Q3 2025, versus 0.77% for Q2 2025 and 0.72% for Q1 2025.